top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

13.06 +0.24 (+1.86%)
Delayed Quote Updated: 2:28 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
News headline image
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone? ↗
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week. 
Via The Motley Fool
Topics Death
News headline image
Why Novavax (NVAX) Stock Is Trading Up Today
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-exp... 
Via StockStory
News headline image
Novavax (NVAX) Q3 2025 Earnings Transcript ↗
Novavax (NVAX) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Novavax (NVAX) Q1 2026 Earnings Transcript ↗
Novavax (NVAX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Novavax (NVAX) Q2 2025 Earnings Transcript ↗
Novavax (NVAX) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars
Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 mill... 
Via StockStory
News headline image
Novavax (NVAX) Q1 Earnings Report Preview: What To Look For
Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be reporting results this Wednesday before market open. Here’s what you need to know. Novavax beat a... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers.... 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings?
Novavax has been treading water for the past six months, recording a small loss of 2.9% while holding steady at $8.34. Is there a buying opportunity in Novav... 
Via StockStory
News headline image
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
Over the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2.1% drop. This might have invest... 
Via StockStory
Topics Stocks
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Avoid
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
News headline image
2 Growth Stocks Set to Flourishand 1 We Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio... 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NVAX) Stock Trades Down, Here Is Why
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 4.1% in the afternoon session after major indices including the S&P 500 and... 
Via StockStory
Topics Economy Government Stocks
News headline image
3 Stocks Under $50 That Concern Us
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline... 
Via StockStory
News headline image
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks to Target This Week and 1 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks That Concern Us
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page